The quest to treat addiction

After his brother overdosed in 2019, Timothy Ko founded Entheon Biomedical (ENBI) on his quest to find a better treatment for addiction through psychedelic therapy.

The company is focused on advancing the DMT molecule to treat substance use disorders. It just submitted a regulatory package to an ethics committee for a human clinical trial on healthy smokers, which will be one of the most comprehensive studies of DMT ever.

Entheon has also begun recruiting patients with treatment-resistant depression for a ketamine therapy study, which will be conducted with Heading Health LLC. The study will use an electroencephalography (EEG) headset and genetic screening to:

  • Understand how ketamine influences brainwave patterns
  • Investigate how genetic markers influence ketamine response
  • Explore the effects of music on therapeutic outcomes
  • Develop a framework for characterizing the psychedelic drug state

PDF of article 1

PDF of article 2

Goodbye styrofoam 👋

M2Bio Rolls Out Sustainable Packaging for Liviana

M2Bio Sciences developed a sustainable alternative to styrofoam out of mushroom mycelium and hemp. 

The foamy material, appropriately named Hempcelium, is fully biodegradable and can even remove industrial toxins from groundwater and soil.

Plus, it takes less energy to produce than styrofoam and can be grown into any shape.

M2Bio will use Hempcelium to safely ship its CBD olive oil products. 

PDF of article

Take a psychedelic retreat from your bed

Startup To Host Psychedelic Trips In The Metaverse

Psychedelic retreats are inaccessible to most due to high costs, length of treatments, and travel restrictions. Who has ten thousand dollars to drop on a week in Jamaica?

That’s why Ei.Ventures is investing (heavily) in the Metaverse.

The company purchased a $2.2M estate in The Sandbox virtual world – the third largest land sale in the Metaverse ever. 

The goal? 

To provide “wondrous” psychedelic journeys through the Hawaiian islands, or outer space, using VR technology.

Sound like the ideal setting for your next trip?

PDF of article

Psychedelic therapy just got A LOT more accessible for Canadians

BREAKING: Canada Opens New Legal Pathways For Access To Psychedelics Treatment With Psilocybin And MDMA

Until now, the only way for patients to access psychedelic therapy outside a clinical trial was to apply for a Section 56 exemption and wait months on end to (possibly) receive approval from Health Canada.

Despite six more patients receiving the exemption over the holidays, the system remains flawed.

Thankfully, this Wednesday, Health Canada made an amendment to this thing called the Special Access Program (SAP), which enables healthcare practitioners to request access to drugs that are not yet approved, but have shown promise in clinical trials.

The amendment allows practitioners to request access to psilocybin and MDMA for their patients with serious, life-threatening, or treatment-adverse conditions. And the best part: requests are typically processed in just 1 day! 🎉

While this does not guarantee access for patients, it certainly feels like a big step in the right direction.

To learn more about the amendment, check out TheraPsil’s free webinar on Jan. 19th.

PDF of article

Benzinga

Could this African shrub solve the opioid crisis?

MindMed Successfully Completes Phase 1 Clinical Trial of 18-MC

MindMed (MNMD) developed a non-hallucinogenic molecule based on ibogaine, the psychoactive compound in the African iboga plant, and it’s showing potential to treat opioid addiction.

How? 🤔

The compound has demonstrated the ability to reduce opioid use and ease withdrawal symptoms by regulating excessive dopamine fluctuations.

An upcoming Phase 2a trial will put the compound to the test.

PDF of article